Articles from Cyllene Therapeutics

Cyllene Therapeutics Appoints Seasoned Biotech Executive Dr Marc Grasso as Chief Financial Officer

Paris, France, New York, USA, Sept. 17, 2026 (GLOBE NEWSWIRE) --

By Cyllene Therapeutics · Via GlobeNewswire · September 17, 2026

Cyllene Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EG110A in Neurogenic Detrusor Overactivity (NDO)

Paris, Sept. 14, 2026 (GLOBE NEWSWIRE) --

By Cyllene Therapeutics · Via GlobeNewswire · September 14, 2026

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) --

By Cyllene Therapeutics · Via GlobeNewswire · July 23, 2026

Cyllene Therapeutics (formerly known as EG 427) Raises €33 Million Series C Financing to Advance Clinical Development of EG110A and Pipeline Expansion

Paris, July 07, 2026 (GLOBE NEWSWIRE) -- Cyllene Therapeutics, formerly known as EG 427, today announced the successful closing of a €33 million Series C financing led by new investors GordonMD Global Investments® LP (“GordonMD”) and M Ventures. Existing investors including Andera Partners SAS, Bpifrance Investissement through its InnoBio 3 Fund, L.P. and Lamond Ventures LLC also participated in the round.

By Cyllene Therapeutics · Via GlobeNewswire · July 7, 2026